EMA To Beef Up Use Of PBPK Models In Drug Development And Evaluation
Executive Summary
New EU guideline will describe how drug developers should go about using physiologically-based pharmacokinetic (PBPK) modeling tools to help predict drug interactions, establish dosing in pediatric or Phase I trials, and other regulatory functions.
You may also be interested in...
FDA Endorses PBPK Modeling To Support Post-Approval Changes
The US FDA endorses the use of physiologically based pharmacokinetic (PBPK) models to support formulation and manufacturing changes.
Better Risk Assessment And Dose Determination Key To EMA's Plans For Updated Phase I Trial Guideline
Proposed revisions to the European Medicines Agency's guideline on first-in-human studies are intended to help identify and reduce the risks to study participants by making better use of non-clinical data in areas like the choice of the therapeutic dose, the dose escalation strategy, and the criteria for stopping a trial.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.